FTC sues to block $28B Am­gen-Hori­zon deal, in move that will send shock­waves through bio­phar­ma M&A

The FTC on Tues­day filed a law­suit to block Am­gen’s pro­posed $28 bil­lion buy­out of Hori­zon Ther­a­peu­tics, a move that Wall Street an­a­lysts have warned could dull M&A en­thu­si­asm across the sec­tor.

The agency ar­gued that the merg­er would al­low Am­gen to use re­bates on its ex­ist­ing drugs to “pres­sure in­sur­ance com­pa­nies and phar­ma­cy ben­e­fit man­agers in­to fa­vor­ing” Hori­zon’s thy­roid eye dis­ease and chron­ic re­frac­to­ry gout prod­ucts: Te­pez­za and Krys­texxa, re­spec­tive­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.